Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025Open Access

A meta analysis of subtype-specific prognostic significance of METTL3 expression in non-small cell lung cancer

View Full Paper
Ask AI
Bookmark
Share

Authors

ZLZichang LiuRJRen JiachenYZYaning Zhang

Discussion

Loading...

Member takes

Overview

Systematic review demonstrates METTL3's role as a prognostic biomarker in lung adenocarcinoma, highlighting its significance over time.

Key Points

  • High METTL3 expression is significantly linked to poorer overall survival in lung adenocarcinoma.
  • Pooled analyses from nine studies show a notable association with HR of 0.79, indicating poorer outcomes.
  • Subgroup analysis indicates a stronger prognostic value of METTL3 in NSCLC after 10 months of follow-up.
  • No significant correlation was found for METTL3 expression in lung squamous-cell carcinoma.

Cite This Study

Liu et al. (2025) studied this question.

synapsesocial.com/papers/68c23c20b210217d64788259https://doi.org/10.21203/rs.3.rs-7301948/v1
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Loss of METTL3 m6A methyltransferase results in short‐term progression and poor treatment outcome of bladder cancer patients2025 · 3 citations
  2. 2The methyltransferase METTL3 promotes the progression of breast cancer cells via regulating EGF m6A modification2025 · 3 citations
  3. 3MET Overexpression Is Associated with Superior Immunotherapy Benefit in Advanced Non-Small Cell Lung Cancer2025
  4. 4METTL3-mediated activation of Sonic Hedgehog signaling promotes breast cancer progression2025 · 1 citations
  5. 5Targeting O-GlcNAcylated METTL3 impedes MDS/AML progression via diminishing SRSF1 m6A modification2025 · 1 citations